Literature DB >> 8814726

The role of 201Tl scintigraphy in evaluating proliferative activity in thyroid neoplasms.

K Nakada1, C Katoh, K Kanegae, E Tsukamoto, K Itoh, M Furudate, N Tamaki.   

Abstract

To identify the relationship between the uptake of 201Tl and the proliferative activity in thyroid neoplasms, 201Tl scintigraphy was performed in 57 patients with thyroid neoplasms. 201Tl uptake ratio was calculated in both the early and the delayed images and then compared with factors representing cellular or practical proliferative activity of the lesions. The labeling index (LI) for proliferating cell nuclear antigen (PCNA) was determined quantitatively by flow cytometry. There was a significant correlation between the uptake ratio and LI for PCNA. The correlation coefficient for the delayed ratio (DR) vs. LI was better than that for the early ratio (ER) vs. LI. As parameters for practical proliferation, the surgical stage in primary thyroid carcinoma or 131I uptake in recurrent thyroid carcinoma was focused on. DR was strongly related to these parameters, regardless of the histopathological features or size of the lesions. Our results suggest that 201Tl uptake in delayed thyroid scan is useful in assessing proliferative activity in thyroid neoplasms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814726     DOI: 10.1007/bf03165052

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  26 in total

1.  Flow cytometric analysis of proliferation associated nuclear antigens using washless staining of unfixed cells.

Authors:  G Landberg; G Roos
Journal:  Cytometry       Date:  1992

2.  Statistical evaluation of the prognostic value of nuclear DNA content in papillary, follicular, and medullary thyroid tumors.

Authors:  M Bäckdahl; J Carstensen; G Auer; E Tallroth
Journal:  World J Surg       Date:  1986-12       Impact factor: 3.352

3.  Thallium activation of the (Na+--K+)-activated ATPase of rabbit kidney.

Authors:  J S Britten; M Blank
Journal:  Biochim Biophys Acta       Date:  1968-04-24

Review 4.  Papillary thyroid carcinoma: factors influencing prognosis and current therapy.

Authors:  E L Mazzaferri
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

5.  Thallium-201-chloride thyroid scintigraphy to evaluate benign and/or malignant nodules: usefulness of the delayed scan.

Authors:  H Ochi; H Sawa; T Fukuda; Y Inoue; H Nakajima; Y Masuda; T Okamura; Y Onoyama; S Sugano; H Ohkita; Y Tei; K Kamino; Y Kobayashi
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

6.  Clinical evaluation of 201thallium chloride scan for thyroid nodule.

Authors:  T Harada; Y Ito; K Shimaoka; T Taniguchi; A Matsudo; T Senoo
Journal:  Eur J Nucl Med       Date:  1980-04

7.  Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis.

Authors:  R L Garcia; M D Coltrera; A M Gown
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

Review 8.  Radionuclides and therapy of thyroid cancer.

Authors:  M J O'Doherty; T O Nunan; D N Croft
Journal:  Nucl Med Commun       Date:  1993-09       Impact factor: 1.690

9.  Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities.

Authors:  N Oriuchi; M Tamura; T Shibazaki; C Ohye; N Watanabe; M Tateno; K Tomiyoshi; T Hirano; T Inoue; K Endo
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

10.  Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle.

Authors:  G Landberg; E M Tan; G Roos
Journal:  Exp Cell Res       Date:  1990-03       Impact factor: 3.905

View more
  1 in total

1.  Clinical significance of thallium-201 SPECT after postoperative radiotherapy in patients with glioblastoma multiforme.

Authors:  Gyo Iida; Kazuhiko Ogawa; Shogo Ishiuchi; Itaru Chiba; Takashi Watanabe; Naofumi Katsuyama; Yoshihiko Yoshii; Sadayuki Murayama
Journal:  J Neurooncol       Date:  2010-09-02       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.